4CMenB tied to modest gonorrhea protection in real-world study - Report - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

4CMenB tied to modest gonorrhea protection in real-world study

The 38.4% reduction in gonorrhea risk “could translate into preventing a substantial number of infections and complications.”

  • By

  • Julia Cipriano, MS, CMPP

  • September 9, 2026

  • 4 min

Share

4CMenB tied to modest gonorrhea protection in real-world study

Overview

A study found that the 4CMenB vaccine showed an effectiveness of 38.4% in reducing gonococcal notifications among adolescents in high-prevalence settings.

Background

Gonorrhea is a significant public health concern, particularly among adolescents, due to its potential complications such as pelvic inflammatory disease and infertility. The close genetic relationship between Neisseria gonorrhoeae and Neisseria meningitidis raises interest in the potential for meningococcal vaccines to provide cross-protection against gonorrhea.

Data Highlights

MeasureValue
Vaccine Effectiveness (2 doses)38.4% (95% CI, 18.6%-53.4%)
Overall Meningococcal Carriage Prevalence4% to 6.2%
Odds Ratio for Carriage Increase1.68 (95% CI, 1.14-2.48)
Percentage of Fully Vaccinated Adolescents9.6%
Percentage Identifying as Aboriginal or Torres Strait Islander42.4%

Key Findings

  • The 4CMenB vaccine provides a two-dose effectiveness of 38.4% against gonorrhea.
  • Vaccinated adolescents had lower gonococcal notifications compared to unvaccinated peers.
  • Meningococcal carriage increased from 4% to 6.2% post-vaccination.
  • Carriage of meningococci associated with disease remained stable.
  • Limitations included lower-than-expected vaccine uptake and missing data in the carriage analysis.

Clinical Implications

Clinicians should continue to emphasize comprehensive screening and prevention practices, especially in high-prevalence populations.

Conclusion

The study indicates that the 4CMenB vaccine may provide modest protection against gonorrhea in adolescents.

Related Resources & Content

  1. Marshall H, Open Forum Infectious Diseases, 2023 -- 4CMenB tied to modest gonorrhea protection in real-world study
  2. The Journal of Infectious Diseases — Cost-effectiveness of 4CMenB Vaccination Against Gonorrhea: Importance of Dosing Schedule, Vaccine Sentiment, Targeting Strategy, and Duration of Protection
  3. Open Forum Infectious Diseases — Exploring the Natural History of Gonorrhea and the Protective Role of 4CMenB: A Call for Further Research and Improved Data Collection
  4. MDSpire News — PrEP Use Linked to Higher Gonorrhea Rate
  5. International Journal of Infectious Diseases — Reassessing the Role of Meningococcal B Vaccination in Preventing Gonorrhoea Among Men Who Have Sex with Men
  6. Clinical Treatment of Gonorrhea | Gonorrhea | CDC
  7. Multidesign Study of 4CMenB Vaccine Effectiveness and Impact on Meningococcal Carriage and Gonorrhea in Northern Territory Adolescents and Young People | Open Forum Infectious Diseases | Oxford Academic
  8. Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post–Program Implementation: Observational Case–Control Study - PMC
  9. Long-term 4CMenB Vaccine Effectiveness Against Gonococcal Infection at Four Years Post–Program Implementation: Observational Case–Control Study | Open Forum Infectious Diseases | Oxford Academic
  10. Efficacy of the meningococcal vaccine against Neisseria gonorrhoeae: a randomised clinical trial (MenGO) - PMC
  11. Meningococcal B Vaccine to Prevent Neisseria gonorrhoeae Infection - PubMed
  12. National gonorrhoea vaccination programme using 4CMenB vaccine: frequently asked questions - GOV.UK

Original Source(s)

4CMenB tied to modest gonorrhea protection in real-world study

  • by Julia Cipriano, MS, CMPP

  • September 9, 2026

Related Content

CDC: Measles cases surpass 4,000 in 2026

CDC data show that 96% of cases are outbreak-associated, with adults accounting for 40% of cases, up from 29% in 2025.

Self-Sampling Shows Test Agreement

The study authors frame the device as a potential way to simplify screening, while emphasizing that larger validation studies are still needed.

FDA approves XFG-adapted COVID-19 vaccine

The 2026 to 2027 formulation aligns with FDA guidance on the preferred composition for COVID-19 vaccines beginning this fall.